Taking peopleNo phase
Follows adults with atrial fibrillation treated with the PulseSelect PFA System
Follows adults with atrial fibrillation who receive the PulseSelect PFA System.
Key facts
- Who runs it
- Medtronic Cardiac Ablation Solutions
- Where
- Grenoble, Le Coudray, Massy, Paris, and Toulouse, FranceSee the 5 sitesAlso in 15 other countries, 38 sites
- Trial code
- Registry title
- PulseSelect™ PFA Global Registry
- Status
- Recruiting
- People taking part
- 1,950 people, planned
- Started
- 23 Jul 2024
- Expected to end
- 31 Jul 2028
- Type of study
- Observational
- Record updated
- 16 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults diagnosed with atrial fibrillation who are planned to have a procedure with the PulseSelect PFA System.
- Age
- 18 years or older, or the minimum age set by local regulations.
- Sex
- All sexes can join.
- Disease stage
- Diagnosed with atrial fibrillation (AF).
Main reasons for not taking part
- Being enrolled in another study that the global study manager has not approved for joint enrolment.
- Meeting exclusion criteria set by local law.
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Subject is ≥ 18 years of age or minimum age as required by local regulations
- Subject has been diagnosed with atrial fibrillation (AF)
- Planned procedure using commercially available PulseSelect™ PFA System
- Willing to comply with study requirements and give informed consent (defined as legally effective, documented confirmation of a subject's voluntary agreement to participate in this clinical study) or authorization per institution and geographical requirements
Who cannot take part
- Subject is enrolled in a concurrent study that has not been approved for concurrent enrollment by the global study manager
- Subject with exclusion criteria required by local law
Where in France
Also in 15 other countries, 38 sites
- Centre Hospitalier Universitaire de Grenoble - Site NordGrenoble, FranceContact: Josman SuriNo longer taking part
- Les Hopitaux de Chartres-Hopital Louis PasteurLe Coudray, FranceContact: Josman SuriNo longer taking part
- Hôpital Privé Jacques CartierMassy, FranceContact: Josman SuriNo longer taking part
- Hôpital Européen Georges PompidouParis, FranceContact: Josman SuriNo longer taking part
- Clinique PasteurToulouse, FranceContact: Josman SuriNo longer taking part
About the trial
What the trial wants to find out
The PulseSelect™ PFA Global Registry is a prospective, global, multi-center, observational post-approval study. Subjects will be treated with the PulseSelect™ PFA System and followed according to SOC.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- PulseSelect PFA Global Registry, a Part of the Medtronic Cardiac Ablation Post-Market Study Platform
- Plain-language title
- Follows adults with atrial fibrillation treated with the PulseSelect PFA SystemGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 16 October 2026